Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrathiomolybdate in High Risk Breast Cancer
NCT00195091Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2003
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tetrathiomolybdate in breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Time to Progression for Patients With Breast Cancer Treated With Study Drug. Started Dec 2003; status: terminated.
02
Drugs
tetrathiomolybdate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00195091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195091.